JP2015524662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524662A5 JP2015524662A5 JP2015525545A JP2015525545A JP2015524662A5 JP 2015524662 A5 JP2015524662 A5 JP 2015524662A5 JP 2015525545 A JP2015525545 A JP 2015525545A JP 2015525545 A JP2015525545 A JP 2015525545A JP 2015524662 A5 JP2015524662 A5 JP 2015524662A5
- Authority
- JP
- Japan
- Prior art keywords
- ids
- human
- polypeptide
- pmol
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 77
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 38
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 30
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 claims description 27
- 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 claims description 26
- 102000057422 human IDS Human genes 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 14
- 210000005260 human cell Anatomy 0.000 claims description 11
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 6
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims description 6
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 108010072166 idursulfase Proteins 0.000 claims description 3
- 229960002396 idursulfase Drugs 0.000 claims description 3
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 244000309466 calf Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000030609 dephosphorylation Effects 0.000 claims 1
- 238000006209 dephosphorylation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000008955 Mucolipidoses Diseases 0.000 description 6
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 5
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102100037364 Craniofacial development protein 1 Human genes 0.000 description 3
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 3
- 208000001905 GM2 Gangliosidoses Diseases 0.000 description 3
- 201000008905 GM2 gangliosidosis Diseases 0.000 description 3
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 3
- 208000024571 Pick disease Diseases 0.000 description 3
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 3
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 description 2
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 description 2
- 102100023364 Ganglioside GM2 activator Human genes 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 2
- 101000940535 Homo sapiens Cold shock domain-containing protein E1 Proteins 0.000 description 2
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 2
- 101000685969 Homo sapiens Ganglioside GM2 activator Proteins 0.000 description 2
- 101000834991 Homo sapiens Transitional endoplasmic reticulum ATPase Proteins 0.000 description 2
- 206010072927 Mucolipidosis type I Diseases 0.000 description 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 2
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108700001567 Type I Schindler Disease Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000008977 glycoproteinosis Diseases 0.000 description 2
- 102000046317 human CSDE1 Human genes 0.000 description 2
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- WDVIDPRACNGFPP-QWRGUYRKSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WDVIDPRACNGFPP-QWRGUYRKSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 102000006772 Acid Ceramidase Human genes 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 1
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 102100022146 Arylsulfatase A Human genes 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 108010023546 Aspartylglucosylaminase Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101710124976 Beta-hexosaminidase A Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 1
- 206010010582 Congenital osteodystrophy Diseases 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000007652 Dysostoses Diseases 0.000 description 1
- 201000001324 Dysostosis Diseases 0.000 description 1
- 208000025127 Erdheim-Chester disease Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
- 208000033149 Farber disease Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- 208000017462 Galactosialidosis Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000020322 Gaucher disease type I Diseases 0.000 description 1
- 208000020916 Gaucher disease type II Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 description 1
- 101001109579 Homo sapiens NPC intracellular cholesterol transporter 2 Proteins 0.000 description 1
- 208000015178 Hurler syndrome Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 108700037017 Hyaluronidase Deficiency Proteins 0.000 description 1
- 208000005503 Hyaluronidase deficiency Diseases 0.000 description 1
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 101150117895 LAMP2 gene Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 206010072928 Mucolipidosis type II Diseases 0.000 description 1
- 206010072929 Mucolipidosis type III Diseases 0.000 description 1
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 1
- 208000025797 Mucopolysaccharidosis type 4A Diseases 0.000 description 1
- 208000025923 Mucopolysaccharidosis type 4B Diseases 0.000 description 1
- 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 description 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 1
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 1
- YTTRPBWEMMPYSW-HRRFRDKFSA-N N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@H]([NH3+])C([O-])=O YTTRPBWEMMPYSW-HRRFRDKFSA-N 0.000 description 1
- 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 1
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 description 1
- 102100022737 NPC intracellular cholesterol transporter 2 Human genes 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 description 1
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 description 1
- 101100029763 Rattus norvegicus Inpp5j gene Proteins 0.000 description 1
- 108091006161 SLC17A5 Proteins 0.000 description 1
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 description 1
- 208000025820 Sanfilippo syndrome type B Diseases 0.000 description 1
- 208000025802 Sanfilippo syndrome type C Diseases 0.000 description 1
- 208000025804 Sanfilippo syndrome type D Diseases 0.000 description 1
- 102000017852 Saposin Human genes 0.000 description 1
- 108050007079 Saposin Proteins 0.000 description 1
- 208000017460 Sialidosis type 2 Diseases 0.000 description 1
- 102100023105 Sialin Human genes 0.000 description 1
- 101710105284 Sialin Proteins 0.000 description 1
- 201000001828 Sly syndrome Diseases 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 1
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 1
- 201000008333 alpha-mannosidosis Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 201000006486 beta-mannosidosis Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 description 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 108010089932 heparan sulfate sulfatase Proteins 0.000 description 1
- 102000056929 human IDUA Human genes 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 201000007769 mucolipidosis Diseases 0.000 description 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
- 208000012253 mucopolysaccharidosis IVA Diseases 0.000 description 1
- 208000000690 mucopolysaccharidosis VI Diseases 0.000 description 1
- 208000036707 mucopolysaccharidosis type 3C Diseases 0.000 description 1
- 208000036725 mucopolysaccharidosis type 3D Diseases 0.000 description 1
- 208000020004 mucopolysaccharidosis type 9 Diseases 0.000 description 1
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 description 1
- 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 description 1
- 208000012224 mucopolysaccharidosis type IIIC Diseases 0.000 description 1
- 208000027333 mucopolysaccharidosis type IIID Diseases 0.000 description 1
- 208000012091 mucopolysaccharidosis type IVB Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 208000011985 sialidosis Diseases 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677959P | 2012-07-31 | 2012-07-31 | |
| US61/677,959 | 2012-07-31 | ||
| PCT/US2013/052939 WO2014022515A1 (en) | 2012-07-31 | 2013-07-31 | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524662A JP2015524662A (ja) | 2015-08-27 |
| JP2015524662A5 true JP2015524662A5 (cg-RX-API-DMAC7.html) | 2016-08-25 |
| JP6433424B2 JP6433424B2 (ja) | 2018-12-05 |
Family
ID=48949266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525545A Expired - Fee Related JP6433424B2 (ja) | 2012-07-31 | 2013-07-31 | 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9932565B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2880156B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6433424B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104662150B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013296557B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3140358A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2647082T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014022515A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222568B2 (en) | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| EP2717917B1 (en) | 2011-07-05 | 2016-04-20 | biOasis Technologies Inc | P97-antibody conjugates |
| EP3321281B1 (en) | 2011-08-05 | 2019-11-27 | biOasis Technologies Inc | P97 fragments with transfer activity |
| AU2013296557B2 (en) | 2012-07-31 | 2019-04-18 | Bioasis Technologies Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| US20160347821A1 (en) | 2014-02-03 | 2016-12-01 | Bioasis Technologies, Inc. | P97 fusion proteins |
| WO2015126729A1 (en) * | 2014-02-19 | 2015-08-27 | Bioasis Technologies, Inc. | P97-ids fusion proteins |
| EP3137610B1 (en) | 2014-05-01 | 2019-03-06 | Bioasis Technologies, Inc. | P97-polynucleotide conjugates |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| RU2673038C2 (ru) * | 2016-01-18 | 2018-11-21 | ООО "Международный Биотехнологический Центр "Генериум" | Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа |
| CN106282231B (zh) * | 2016-09-06 | 2020-01-03 | 陕西慧康生物科技有限责任公司 | 粘多糖贮积症ii型动物模型的构建方法及应用 |
| WO2018089789A1 (en) | 2016-11-10 | 2018-05-17 | The Research Foundation For The State University Of New York | System, method and biomarkers for airway obstruction |
| WO2019051297A1 (en) * | 2017-09-08 | 2019-03-14 | The Nemours Foundation | AGENT, DEVICE AND BLOOD CIRCULATION SYSTEM FOR TREATING LYSOSOMAL DISEASES, AND METHODS OF TREATING LYSOSOMAL DISEASES |
| EP3692070A1 (en) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| JP7577650B2 (ja) * | 2018-10-10 | 2024-11-05 | アミカス セラピューティックス インコーポレイテッド | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
| CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
| CN110609078B (zh) * | 2019-09-20 | 2022-03-11 | 南京谱利健生物技术有限公司 | 一种检测蛋白磷酸化和乙酰氨基葡萄糖化关联作用的方法 |
| KR20230086703A (ko) | 2020-10-14 | 2023-06-15 | 데날리 테라퓨틱스 인크. | 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법 |
| CA3226269A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| CA3228179A1 (en) * | 2021-08-18 | 2023-02-23 | Joint-Stock Company "Generium" | Targeted delivery of therapeutic enzymes |
| CN114181318B (zh) * | 2021-11-08 | 2023-08-01 | 四川大学 | 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用 |
| WO2023204202A1 (ja) * | 2022-04-19 | 2023-10-26 | Ｊｃｒファーマ株式会社 | マンノース－６－リン酸の数を減少させた糖蛋白質 |
| EP4397687A4 (en) * | 2022-04-28 | 2025-09-24 | Linno Pharmaceuticals Inc | RECOMBINANT HARSA TO CROSS THE BLOOD-BRAIN BARRIER |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4489710A (en) | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5186941A (en) | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4801542A (en) | 1984-10-12 | 1989-01-31 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB2188637B (en) | 1986-02-07 | 1990-11-14 | Oncogen | Vaccines against melanoma |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| DE3815826A1 (de) | 1988-05-09 | 1989-11-23 | Henkel Kgaa | Verfahren zur herstellung von vicinal diacyloxysubstituierten verbindungen |
| US5470829A (en) | 1988-11-17 | 1995-11-28 | Prisell; Per | Pharmaceutical preparation |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| ES2136595T5 (es) | 1989-04-19 | 2004-04-01 | Enzon, Inc. | Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos. |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| IL90193A (en) | 1989-05-04 | 1993-02-21 | Biomedical Polymers Int | Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US6018031A (en) | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5312808A (en) | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
| US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
| NL194941C (nl) | 1990-02-15 | 2003-08-04 | Cordis Corp | Werkwijze voor het aanbrengen van een fysiologisch actieve verbinding op een substraatoppervlak. |
| US5275838A (en) | 1990-02-28 | 1994-01-04 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| WO1992000748A1 (en) | 1990-07-06 | 1992-01-23 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| FR2672053B1 (fr) | 1991-01-30 | 1993-04-23 | Atochem | Polyether bloc amides, leur procede de synthese. |
| FR2673946B1 (fr) | 1991-03-15 | 1993-05-28 | Atochem | Polyether bloc amides, leur procede de synthese. |
| CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5932211A (en) | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1993016118A1 (en) | 1992-02-13 | 1993-08-19 | Carlsberg A/S | Polyethylene or polypropylene glycol containing polymer |
| EP1018343A1 (en) | 1992-07-10 | 2000-07-12 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| US20020119095A1 (en) | 1992-07-10 | 2002-08-29 | Reinhard Gabathuler | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
| US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| WO1994004193A1 (en) | 1992-08-21 | 1994-03-03 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| AU7109494A (en) | 1993-06-16 | 1995-01-03 | Enzon, Inc. | Conjugated biodhesives |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5618528A (en) | 1994-02-28 | 1997-04-08 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
| UA41929C2 (uk) | 1994-03-17 | 2001-10-15 | Мерк Патент Гмбх | Анти-ефрр одноланцюжковий fv,молекула днк,яка його кодує, анти-ефрр антитіло,спосіб одержання анти-ефрр одноланцюжкового fv,спосіб одержання повного анти-ефрр антитіла та фармацевтична композиція (варіанти) |
| US5686110A (en) | 1994-06-02 | 1997-11-11 | Enzon, Inc. | Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5756593A (en) | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| CA2226299A1 (en) | 1995-08-11 | 1997-02-27 | Dendritech, Inc. | Hyper comb-branched polymer conjugates |
| PT876165E (pt) | 1995-12-18 | 2006-10-31 | Angiotech Biomaterials Corp | Composicoes de polimeros reticulados e processos para a sua utilizacao |
| KR20000029673A (ko) | 1996-08-02 | 2000-05-25 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 단일의공유결합된ｎ-말단수용성폴리머를갖는폴리펩티드 |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| EP1037649B1 (en) | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| CA2323048C (en) | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US6419934B1 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US7214658B2 (en) | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
| US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6537549B2 (en) | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6507788B1 (en) | 1999-02-25 | 2003-01-14 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function |
| US6642038B1 (en) * | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
| NZ518143A (en) | 1999-10-08 | 2004-04-30 | Nektar Therapeutics Al Corp | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| JP2003525038A (ja) | 2000-02-08 | 2003-08-26 | ユニバーシティー オブ ブリティッシュ コロンビア | 治療薬をスクリーニングするための組成物および方法 |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| CA2443555C (en) | 2000-05-01 | 2016-07-19 | Christopher M. Starr | Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly |
| WO2002013873A2 (en) | 2000-08-17 | 2002-02-21 | Synapse Technologies, Inc. | P97-active agent conjugates and their methods of use |
| WO2002013843A2 (en) | 2000-08-17 | 2002-02-21 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| KR20030074839A (ko) | 2001-02-19 | 2003-09-19 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체 |
| MXPA03011365A (es) | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| EP1554572B1 (en) | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| DK2322229T3 (en) | 2001-10-10 | 2017-03-27 | Novo Nordisk As | Remodeling and Glycoconjugation of Factor IX |
| US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2003222568B2 (en) | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| WO2004078215A2 (en) | 2003-02-28 | 2004-09-16 | The Board Of Trustees Of The University Of Illinois | Use of antibody conjugated deoxycytidine kinase for adept |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| AU2004280143A1 (en) | 2003-10-11 | 2005-04-21 | Tekmira Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| BRPI0507440A (pt) | 2004-02-06 | 2007-07-10 | Biomarin Pharm Inc | fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US8236306B2 (en) | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
| ATE461220T1 (de) | 2005-11-12 | 2010-04-15 | Lilly Co Eli | Anti-egfr-antikörper |
| EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| DK2308514T3 (da) | 2007-03-23 | 2013-09-02 | To Bbb Holding B V | Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| JP2010535484A (ja) | 2007-08-08 | 2010-11-25 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | トランスフェリン変異体と複合体 |
| DK2644194T3 (en) | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| HRP20190690T1 (hr) * | 2009-10-09 | 2019-06-28 | Armagen, Inc. | Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu |
| EP2560687B1 (en) | 2010-04-19 | 2017-05-24 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| FR2959229B1 (fr) | 2010-04-21 | 2013-01-18 | Vect Horus | Derives peptidiques, leur preparation et leurs utilisations |
| CN103260637B (zh) * | 2010-06-25 | 2016-04-06 | 夏尔人类遗传性治疗公司 | 乙酰肝素n-硫酸酯酶cns递送的方法和组合物 |
| SMT201600385T1 (it) * | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| US8545837B2 (en) * | 2010-06-25 | 2013-10-01 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of iduronate-2-sulfatase |
| KR101535791B1 (ko) | 2010-11-12 | 2015-07-10 | 주식회사 녹십자 | 개량형 이듀로네이트-2-설파타제 및 이의 용도 |
| EP2717917B1 (en) | 2011-07-05 | 2016-04-20 | biOasis Technologies Inc | P97-antibody conjugates |
| EP3321281B1 (en) | 2011-08-05 | 2019-11-27 | biOasis Technologies Inc | P97 fragments with transfer activity |
| CA2872226A1 (en) | 2012-05-02 | 2013-11-07 | Symphogen A/S | Humanized pan-her antibody compositions |
| US20140004097A1 (en) | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| AU2013296557B2 (en) | 2012-07-31 | 2019-04-18 | Bioasis Technologies Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| US8753426B2 (en) | 2012-08-03 | 2014-06-17 | Air Products And Chemicals, Inc. | Polymers, polymer membranes and methods of producing the same |
| CA2889608A1 (en) | 2012-10-26 | 2014-05-01 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to cell types |
| GB201303308D0 (en) | 2013-02-25 | 2013-04-10 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
| US20160347821A1 (en) | 2014-02-03 | 2016-12-01 | Bioasis Technologies, Inc. | P97 fusion proteins |
| WO2015126729A1 (en) | 2014-02-19 | 2015-08-27 | Bioasis Technologies, Inc. | P97-ids fusion proteins |
| EP3137610B1 (en) | 2014-05-01 | 2019-03-06 | Bioasis Technologies, Inc. | P97-polynucleotide conjugates |
| WO2017123928A1 (en) | 2016-01-13 | 2017-07-20 | Bioasis Technologies, Inc. | Blood-brain barrier vector compounds and conjugates thereof |
-
2013
- 2013-07-31 AU AU2013296557A patent/AU2013296557B2/en not_active Ceased
- 2013-07-31 WO PCT/US2013/052939 patent/WO2014022515A1/en not_active Ceased
- 2013-07-31 CA CA3140358A patent/CA3140358A1/en active Pending
- 2013-07-31 CN CN201380048133.XA patent/CN104662150B/zh not_active Expired - Fee Related
- 2013-07-31 ES ES13747600.8T patent/ES2647082T3/es active Active
- 2013-07-31 CA CA2880162A patent/CA2880162C/en active Active
- 2013-07-31 JP JP2015525545A patent/JP6433424B2/ja not_active Expired - Fee Related
- 2013-07-31 EP EP13747600.8A patent/EP2880156B1/en not_active Not-in-force
- 2013-07-31 US US13/955,794 patent/US9932565B2/en active Active
-
2018
- 2018-04-02 US US15/943,160 patent/US11034943B2/en not_active Expired - Fee Related
-
2021
- 2021-06-11 US US17/345,660 patent/US20210388330A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524662A5 (cg-RX-API-DMAC7.html) | ||
| Ellison et al. | Advances in therapies for neurological lysosomal storage disorders | |
| US11034943B2 (en) | Dephosphorylated lysosomal storage disease proteins and methods of use thereof | |
| JP2016037504A5 (cg-RX-API-DMAC7.html) | ||
| US9932568B2 (en) | Peptide linkers for polypeptide compositions and methods for using same | |
| EP1981546B1 (en) | Enzyme replacement therapy for treating lysosomal storage diseases | |
| IL291554B2 (en) | Administering therapeutic agents to the central nervous system | |
| Kaur et al. | Enzymes as drugs: an overview. | |
| JP2019506164A (ja) | 治療学的酵素類の結合体 | |
| EP3650039A1 (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| AU2019202865B2 (en) | Peptide linkers for polypeptide compositions and methods for using same | |
| WO2016077356A9 (en) | Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof | |
| Neufeld | Enzyme replacement therapy–a brief history | |
| Beck | Emerging drugs for lysosomal storage diseases | |
| Gigliobianco et al. | New advanced strategies for the treatment of lysosomal diseases affecting the central nervous system | |
| EP2029740B1 (en) | Use of polysaccharides for promotion of enzymatic activity | |
| Vartanyan et al. | Causal therapies in mucopolysaccharidoses: enzyme replacement therapy | |
| Winkel | Enzyme Therapy in Non-classic Pompe’s Disease: Safety and efficacy of recombinant human a-glucosidase from milk of transgenic rabbits and from Chinese hamster ovary cells | |
| Im et al. | Overview of the Treatment of Lysosomal Storage Diseases | |
| Matzner | Therapy of lysosomal storage diseases | |
| WO2019051297A1 (en) | AGENT, DEVICE AND BLOOD CIRCULATION SYSTEM FOR TREATING LYSOSOMAL DISEASES, AND METHODS OF TREATING LYSOSOMAL DISEASES | |
| HK1210808B (en) | Dephosphorylated lysosomal storage disease proteins and methods of use thereof | |
| Jones | Alternative Treatment Options: Enzyme Replacement and Small Molecule Therapies | |
| HK1193352A (en) | Peptide linkers for polypeptide compositions and methods for using same |